VERTEX PHARMACEUTICALS INC / MA Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $6.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $6.30M, a 56.55% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $14.50M.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month as first filed |
|---|---|---|
| 2025-12-31 | $6.30M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $14.50M 10-K · filed 2026-02-13 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-13 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-13 | |
| 2021-12-31 | $0.00 10-K · filed 2022-02-09 | |
| 2020-12-31 | $0.00 10-K · filed 2022-02-09 | |
| 2019-12-31 | $500.00K 10-K · filed 2022-02-09 | $478.00K 10-K · filed 2020-02-13 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | |
| 2016-12-31 | $0.00 10-K · filed 2017-02-23 | |
| 2015-12-31 | $455.00K 10-K · filed 2017-02-23 | |
| 2014-12-31 | $1.12M 10-K · filed 2016-02-16 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-13 | |
| 2012-12-31 | $0.00 10-K · filed 2014-02-11 | |
| 2011-12-31 | $0.00 10-K · filed 2013-03-01 | -$23.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |